Navigation Links
Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
Date:9/12/2013

LONDON, September 12, 2013 /PRNewswire/ --

The U.S. equity market ended on a mixed note on Wednesday, September 11, 2013. The S&P 500 and the Dow Jones Industrial Average gained 0.31% and 0.89%, respectively, while the NASDAQ Composite fell by 0.11%. Shares in the biotechnology industry ended lower, even as the broader market finished on a mixed note. The major movers included Gilead Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and InterMune Inc. (NASDAQ: ITMN). AAAResearchReports.com free coverage on GILD, HALO, NPSP, and ITMN is available upon registration at:

http://www.aaaresearchreports.com/register/  

Shares in Gilead Sciences Inc. ended slightly higher on Wednesday, extending their gains from previous trading sessions. The company's shares ended the day 0.11% higher at $62.93 after oscillating between $62.18 and $63.30. A total of 5.46 million shares were traded, which is below the daily average volume of 8.45 million. The company's stock has rallied 20.00% in the last three months and 6.28% in the last one month, compared to a gain 3.87% and a loss of 0.14% in the S&P 500 during the respective periods. Further, Gilead Sciences Inc.'s stock is trading above its 50-day and 200-day moving averages of $58.82 and $48.77, respectively. Download free technical research on GILD by signing up at:

http://www.AAAResearchReports.com/GILD091213.pdf

Halozyme Therapeutics Inc.'s shares fell sharply on Wednesday, even as the broader market ended on a mixed note. The comp
'/>"/>

SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
2. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
3. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
4. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
5. Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review
6. BC Technical Acquires MEDX
7. Call for Papers for Pittcon 2014 Technical Program
8. Technical Workshops at OrthoTec 2013 Focus on Risk Management Throughout Medical Device Lifecycle and Robust Material Selection Process Development
9. Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013
10. 20% Off Your Entire Order of Scientific, Technical, Medical (STM) Book Titles Until the End of March at Chemical Publishing Company
11. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , Catalog Number, Pack ... 100 g, , , , , , ... German , version - 42 K , ... Material Safety , Data Sheets, , MSDS , ...
... , , , , , , , ... , 1691104, Set, ... Package , Inserts/Product Instructions , , English , ... - 24 K , , US Material Safety , Data Sheets , ...
... , Here are some troubleshooting hints that we have gathered , regarding misincorporation or low fidelity of PCR ... , , , , ... , , <a , ... , , , ...
Cached Biology Technology:Trouble-shooting: Misincorporation or low fidelity 2Trouble-shooting: Misincorporation or low fidelity 3
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... 17, 2014The development of stem cell therapies to cure ... characterize stem cell populations based on cell surface markers. ... new marker that is highly expressed in a type ... which they describe in an article in BioResearch ... Liebert, Inc., publishers. The article is available free on ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
... in prospect with a clinical drug trial to begin in ... would open the way to relief in the 10% of ... over 500,000,000 people. , The Walter and Eliza Hall ... Guinea Institute of Medical Research (PNGIMR) and the University of ...
... Medical Center (SFVAMC) and the University of California, San ... bronchitis, which is thought to lead to obliterative bronchitis ... transplanted lungs. , The researchers hope their results will ... standard test for chronic lung rejection, as well as ...
Cached Biology News:Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2
... Immulon 2HB ELISA strips, high binding ... affinity for hydrophilic proteins and complexes. ... for reagent injection while providing the ... Each strip accomodates 12 wells., ...
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: